TY - JOUR
T1 - Instruments for Screening, Diagnosis, and Management of Patients with Generalized Acquired Hypoactive Sexual Desire Disorder
AU - Derogatis, Leonard R.
AU - Revicki, Dennis A.
AU - Clayton, Anita H.
N1 - Publisher Copyright:
© 2020, Mary Ann Liebert, Inc., publishers 2020.
PY - 2020/6/1
Y1 - 2020/6/1
N2 - Screening, diagnosis, and management of hypoactive sexual desire disorder (HSDD) and research into the condition have been challenging due to its biopsychosocial complexity and lack of consensus on relevant measures. Although physician interviews yield much clinically valid information, self-reported questionnaires appear more acceptable to patients and physicians. Consequently, validated patient-reported outcome (PRO) tools are essential for evaluation and management of HSDD, including any therapeutic intervention. The US Food and Drug Administration (FDA) has issued guidance on the use of appropriate endpoints and associated measures for female sexual dysfunction, including HSDD. Although many of the available measures were not designed specifically for HSDD assessment, as per FDA guidelines, most clinical studies have used individual domains or items from established tools, such as the Female Sexual Function Index-desire domain and Item 13 of the revised Female Sexual Distress Scale. For clinical practice, several professional societies recommend the Decreased Sexual Desire Screener and/or a sexual history as tools to diagnose HSDD. This review discusses frequently used PRO tools as well as the newly developed and validated Elements of Desire Questionnaire, which may be appropriate for clinical trials or clinical practice.
AB - Screening, diagnosis, and management of hypoactive sexual desire disorder (HSDD) and research into the condition have been challenging due to its biopsychosocial complexity and lack of consensus on relevant measures. Although physician interviews yield much clinically valid information, self-reported questionnaires appear more acceptable to patients and physicians. Consequently, validated patient-reported outcome (PRO) tools are essential for evaluation and management of HSDD, including any therapeutic intervention. The US Food and Drug Administration (FDA) has issued guidance on the use of appropriate endpoints and associated measures for female sexual dysfunction, including HSDD. Although many of the available measures were not designed specifically for HSDD assessment, as per FDA guidelines, most clinical studies have used individual domains or items from established tools, such as the Female Sexual Function Index-desire domain and Item 13 of the revised Female Sexual Distress Scale. For clinical practice, several professional societies recommend the Decreased Sexual Desire Screener and/or a sexual history as tools to diagnose HSDD. This review discusses frequently used PRO tools as well as the newly developed and validated Elements of Desire Questionnaire, which may be appropriate for clinical trials or clinical practice.
KW - Female Sexual Distress Scale
KW - Female Sexual Function Index
KW - female sexual dysfunction
KW - hypoactive sexual desire disorder
KW - patient-reported outcomes
UR - http://www.scopus.com/inward/record.url?scp=85086418974&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85086418974&partnerID=8YFLogxK
U2 - 10.1089/jwh.2019.7917
DO - 10.1089/jwh.2019.7917
M3 - Article
C2 - 32096691
AN - SCOPUS:85086418974
SN - 1540-9996
VL - 29
SP - 806
EP - 814
JO - Journal of Women's Health
JF - Journal of Women's Health
IS - 6
ER -